Kareo vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Merged with PatientPop → Tebra 2021; $222M funding; $1B+ valuation; $72M 2023 (Golub); 100K providers; 90M patients; 1,000 employees; practice management/EHR leader
About
Kareo was founded in 2004 by Dan Rodrigues to build purpose-designed practice management and billing software for independent physician practices — a segment underserved by legacy healthcare IT vendors focused on hospital systems. The platform addressed the full administrative workflow of a small medical practice: appointment scheduling, patient registration, insurance eligibility verification, charge capture, medical billing, and accounts receivable management. Kareo also developed an integrated EHR module, making it one of the few vendors to combine clinical documentation and practice management in a cloud-native platform accessible to solo practitioners.\n\nKareo's products included Kareo Billing for RCM, Kareo Clinical for EHR and documentation, and Kareo Engage for patient communication and online reputation management. The platform served primary care, mental health, physical therapy, and chiropractic specialties. Its cloud-based delivery — accessible via browser and mobile without on-premises infrastructure — resonated strongly with independent practices managing lean overhead. A managed RCM service and QuickBooks integration rounded out the offering.\n\nKareo merged with PatientPop, a digital practice growth platform, in 2021 to form Tebra — targeting the full lifecycle of independent practice management from marketing through billing. The combined company has raised $222 million in total funding, achieved a $1 billion+ valuation, and serves over 100,000 providers across 90 million patients. Tebra continues operating the Kareo brand for billing and EHR while integrating PatientPop's digital presence capabilities into a unified independent practice growth platform.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.